Supratentorial Glioblastoma Clinical Trial
Official title:
Prognostic Impact of Surgical Resection Extent for Supratentorial High Grade Gliomas.
Prospective randomized controlled clinical trials (single arm study) of surgical treatment modalities for supratentorial high grade gliomas within the next two years.
Supratentorial high grade gliomas are for surgical resection in any case according to many
factors.
Investigators will compare the outcomes/survival rate and clinical outcome of the different
resection types (Total, near total, subtotal/debulking) of supratentorial high grade gliomas
according to the clinical condition and comorbidities of the patient, the location and
morphology of the lesion, the grading of lesions, and the clinical experience of the
neurosurgeon.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Suspended |
NCT03197506 -
Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
|
Phase 2 | |
| Active, not recruiting |
NCT01430351 -
Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy
|
Phase 1 | |
| Active, not recruiting |
NCT04479241 -
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
|
Phase 2 | |
| Active, not recruiting |
NCT03732352 -
18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma
|
Phase 2 | |
| Withdrawn |
NCT04105374 -
Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05052957 -
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
|
Phase 2 | |
| Completed |
NCT02311920 -
Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
|
Phase 1 | |
| Completed |
NCT00884741 -
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
|
Phase 3 |